(188)Re radiopharmaceuticals for radiosynovectomy: evaluation and comparison of tin colloid, hydroxyapatite and tin-ferric hydroxide macroaggregates by Savio, Eduardo et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Nuclear Medicine
Open Access Research article
188Re radiopharmaceuticals for radiosynovectomy: evaluation and 
comparison of tin colloid, hydroxyapatite and tin-ferric hydroxide 
macroaggregates
Eduardo Savio*1, María Cristina Ures1, Patricia Zeledón2, Victoria Trindade1, 
Andrea Paolino1, Virginia Mockford1, Antonio Malanga3, 
Marcelo Fernández1 and Javier Gaudiano4
Address: 1Cátedra de Radioquímica. Facultad de Química. Universidad de la República. Montevideo, Uruguay, 2Servicio de Medicina Nuclear. 
Hospital San Juan de Dios. San José de Costa Rica, Costa Rica, 3Cátedra de Farmacotecnia. Facultad de Química. Universidad de la República. 
Montevideo, Uruguay and 4Centro de Medicina Nuclear. Hospital de Clínicas. Facultad de Medicina. Universidad de la República. Montevideo, 
Uruguay
Email: Eduardo Savio* - esavio@fq.edu.uy; María Cristina Ures - cures@fq.edu.uy; Patricia Zeledón - pplaze@yahoo.com; 
Victoria Trindade - vitoritate@adinet.com.uy; Andrea Paolino - apaolino@fq.edu.uy; Virginia Mockford - ginia81@latinmail.com; 
Antonio Malanga - amalanga@fq.edu.uy; Marcelo Fernández - mferna@iibce.edu.uy; Javier Gaudiano - gaudiano@hc.edu.uy
* Corresponding author    
Abstract
Background: Radiosynovectomy is a therapy used to relieve pain and inflammation from rheumatoid arthritis and related
diseases. In this study three 188Re particulate compounds were characterized according to their physico-chemical properties and
their biological behavior in rabbits. The results were compared in order to establish which was the radiopharmaceutical that
better fits the requirements of this kind of radiotherapy.
Methods:  Three radiopharmaceutical formulations, tin colloid, hydroxyapatite particles (HA) and ferric hydroxide
macroaggregates coated with tin colloid (FHMA), were physically characterized (number, volume and surface of the particles).
For this purpose laser diffraction methodology was used. To evaluate cavity leakage of activity the following studies in New
Zealand rabbits were performed: scintigraphic images for 48 hr after intraarticular injection of each radiopharmaceutical,
biodistribution at 48 hr and urine samples collection during the first 24 hr post-radiopharmaceutical administration.
Results: Labeling procedures for 188Re-HA and 188Re-Sn-FHMA were labour intensive while 188Re-Sn was easily prepared.
Furthermore, 188Re-Sn colloid offered the greatest surface area in the 2–10 microm range and was obtained with a radiochemical
purity over 95%, while percentage of bound activity for 188Re-HA and 188Re-Sn-FHMA were 55% and 92% respectively. Stability
was verified for the three radiopharmaceuticals for 24 hr. Scintigraphic studies and biodistribution in rabbits after intraarticular
administration of the radiopharmaceuticals showed relevant activity only in the knee, this being over 90% of the residual activity
in the whole body at 48 hr in every case. Renal elimination of 188Re-Sn colloid and 188Re-Sn-FHMA was detected by activity
measurements in urine samples, during the first 12 hr post-radiopharmaceutical injection.
The percentage of activity retained in the knee was 69.1% for 188Re-Sn colloid, 55.1% for 188Re-Sn-FHMA and 33.6% for 188Re-
HA.
Conclusion: The 188Re-Sn colloid was easy to prepare, minimum facilities were required, was stable for 24 hr and showed
minimal leakage from the joint after intraarticular injection into the rabbit's knee. Furthermore, 188Re-Sn colloid has greater
retention in the knee when it is compared with the other radiopharmaceuticals, so it could provide the best therapeutic effect/
absorbed dose ratio for the patient.
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Background
Three principal diseases associated with synovia hypertro-
phy are rheumatoid arthritis, hemophilic joint disease
(principally related to bleeding into the joint), and some
cases of traumatic joint disorders. The number of hemo-
philic patients is relatively small. In contrast, rheumatoid
arthritis affects 1–2% of the world's population with a
preponderance of men over women [1,2]. Cellular recruit-
ment and proliferation, with subsequent formation of
synovial granulation tissue (pannus) and an increased
secretion of synovial fluid characterize the inflammatory
process. Progression of the disease leads to the destruction
of the joint or loss of function. Surgery is the last option
as a conventional technique for treating intractable joint
disease after pharmacological therapies have failed, but
removal of all the tissue is not frequently achieved and so
there is high recurrence after 3 to 5 years [2]. Radiation
synovectomy provides an interesting alternative because
cartilage is relatively radioresistent, so a radioactive agent
with effective soft tissue penetration can be administered
directly into the joint, causing no harm to the adjacent
cartilage. As beta radiation can penetrate only a few hun-
dred cell diameters, microparticles labeled with beta emit-
ting radionuclides are effective in treating the disease by
radiation in confined spaces without endangering nearby
normal tissues [2]. Radiopharmaceutical particle size
must be small enough to be phagocyted by the superficial
cells of the sinovium, but not so small as to facilitate a fast
biological clearance by diffusion from the joint [2,3].
Many beta emitters, and many other particulate chemical
compounds have been used as radiosynovectomy agents
[4-6]. In this study 188Re is the chosen radionuclide as it is
readily available on routine basis from the 188W/188Re
generator. The radionuclide 188Re, has a β-ray emission of
sufficient energy (2.11 MeV) to penetrate 5–10 mm of
thickened synovial membrane, and its low-level γ-ray
emission (155 keV) makes scintigraphic monitoring pos-
sible, without harming patients or practitioners. Its half-
life (16.9 hr) is adequate in terms of obtaining an appro-
priate therapeutic effect or for handling of the agent,
avoiding hazardous residual effects.
In this study, particulate chemical compounds such as tin
colloid, hydroxyapatite particles and ferric hydroxide
macroaggregates were compared from the physico-chemi-
cal and biological point of view.
The most important criteria of therapeutically useful radi-
olabeled microparticles are their physico-chemical charac-
teristics such as size range, surface area and volume,
insolubility in aqueous media and irreversible attachment
of radionuclide to the particles [1,2,7]. The best method
of particle size determination is electron microscopy and
more recently laser scattering, both of which provide
information on particle number, size and size distribu-
tion. The last of these is used in this study.
Radiopharmaceutical leakage from the knee was evalu-
ated by the acquisition of scintigraphic images over 48 hr
after intraarticular administration of the radiolabeled
preparations to New Zealand rabbits. Biodistribution
studies were also performed.
The results were compared in order to establish which was
the radiopharmaceutical that best fits the requirements of
this kind of therapy.
Methods
Radiopharmaceutical composition
Four radiopharmaceutical kits were prepared according to
the following formulations:
188Re-Tin colloid [8]
• 15 mg SnCl2.2H2O
• 0.5 mL HCl 0.1 N
• N2 atmosphere
188Re-Hydroxyapatite particles (Indirect method) [1]
First step: preparation of 188Re-HEDP kit
• 10 mg HEDP (free acid)
• 3 mg gentisic acid
• 0.3 mg KReO4
• 3.8 mg SnCl2.2H2O
Second step: preparation of 188Re-Hydroxyapatite (HA)
particles kit:
• 40 mg Hydroxyapatite (Ceramed, Type II, 20 um, CAT
N° 157-2000)
• 650 µL 0.9% saline solution
• 50 µL of 20% Tween 80 (in water)
• 100 µL of SnCl2.2H2O solution (4 mg/mL)
• N2 atmosphere
188Re-Hydroxyapatite particles (Direct method) [9]BMC Nuclear Medicine 2004, 4 http://www.biomedcentral.com/1471-2385/4/1
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• 40 mg Hydroxyapatite (Ceramed, Type II, 20 µm, CAT
N° 157-2000)
• 20 mg SnCl2.2H2O
• 13.7 mg K2C2O4.H2O
pH was adjusted to 1.5 with HCl 0.75 N
188Re-Ferric Hydroxide Macroaggregates, modified from
Castro M, Portilla A. [10]
First step: preparation of 188Re-Tin colloid:
• 15 mg SnCl2.2H2O
• 0.5 mL HCl 0.1 N
• N2 atmosphere
Second step: preparation of 188Re-Ferric Hydroxide Mac-
roaggregates (FHMA):
• 1.8 mL FeSO4.7H2O (7.36 mg/mL)
• 0.7 mL NaOH 0.1 N
• 1.1 mL 0.9% saline solution
• 0.6 mL PVP K30 (16 mg/mL)
• 3 mL PVP K30 (16 mg/mL) pH 8.5
All reagents used were analytical grade.
Equipment
• Dose calibrator system: Capintec Radioisotope Calibra-
tor CRC 5
• Solid scintillation counter NaI(Tl) 3 × 3": EG&G ORTEC
Multichannel Analyzer
• Particle size analyzer: Particle Size Analyzer Coulter ®
• Gammacamera: Sophy Camera DSX
Labeling procedure and quality control
The  188Re used in all formulations were eluted from a
188W/188Re generator (Oak Ridge Laboratories, United
States).
188Re-Tin colloid
The 188Re-Sn colloid was labeled by the addition of 500
µCi (18.5 MBq) of 188ReO4
-  to the kit formulation
described above, then it was autoclaved for 1 hour. pH
was adjusted to 6.0 with the addition of NaOH 1.0 N.
Radiochemical purity was determined by paper chroma-
tography (Whatmann 1) using 0.9% saline solution as the
mobile phase. Radioactivity was measured with a NaI(Tl)
solid scintillation counter.
188Re-Hydroxyapatite particles (Direct method)
40 mg of hydroxyapatite particles were mixed in a centri-
fuge tube with 13.7 mg K2C2O4.H2O and 20 mg
SnCl2.2H2O with 0.3 mL of distilled water. 3 mCi (111
MBq) of 188ReO4
- (contained in 0.4 mL) was added to the
tube. The pH of the reaction mixture was made acidic (pH
1.5) by slow addition of HCl 0.75 N. The suspension was
vortexed and incubated at room temperature for 1 hour. 1
mL of ascorbic acid (10 mg/mL) was added to the suspen-
sion at the end of the hour and was centrifuged at 2000
rpm for 2 minutes. Activity in supernatant and particles
was measured in a dose calibrator system. The particles
were washed twice with 2 mL of ascorbic acid. The activity
of the particles and washings was also measured. The final
suspension was made in ascorbic acid (10 mg/mL, pH 5).
The percentage of bound activity was determined by
measuring the activity of both particles and supernatant
solution in a dose calibrator. From these data the percent-
age of labeled particles yield was calculated.
188Re-Hydroxyapatite particles (Indirect method)
First step: preparation of  188Re-HEDP. 188Re-HEDP was pre-
pared by adding 1 mL of a 188ReO4
- solution (11 mCi /
414 MBq) to a vial containing the lyophilized HEDP kit
formulation described above (pH ≈ 1). The solution was
heated in a water bath for 10 minutes at 100°C.
Radiochemical purity of 188Re-HEDP was determined by
the paper chromatography method using a solution of
HEDP 0.01 M in saline/Whatmann 3 MM and acetone/
Whatmann 1 to determine 188ReO4-,  188Re-HEDP and
reduced hydrolyzed 188Re species respectively.
Second step: preparation of  188Re-HA. 188Re-Hydroxyapatite
particles were prepared by sequential addition of the fol-
lowing materials to a centrifuge tube containing 40 mg of
hydroxyapatite particles: 650 µL of N2-purged saline, 200
µL of 188Re-HEDP (4 mCi / 148 MBq), 50 µL of 20%
Tween 80 in water and 100 µL of a N2-purged SnCl2.2H2O
solution (4 mg/mL). The mixture was incubated for 1
hour at room temperature with occasional stirring. 4 mL
of saline solution was added to the contents of the tube
and then centrifuged at 2000 rpm for 4 minutes. The
supernatant and the particles were separated. The 188Re-
Hydroxyapatite particles were resuspended with 3 mL of
saline solution.BMC Nuclear Medicine 2004, 4 http://www.biomedcentral.com/1471-2385/4/1
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The percentage of bound activity was determined by
measuring the activity of both particles and supernatant
solution in a dose calibrator. From these data the percent-
age of labeled particles yield was calculated.
188Re-Sn-Ferric Hydroxide Macroaggregates
First step: preparation of  188Re-Sn colloid: The 188Re-Sn col-
loid was labeled by the addition of 500 µCi (18.5 MBq) of
188ReO4
- to the kit formulation described above, then it
was autoclaved for 1 hour.
Radiochemical purity was determined by paper chroma-
tography (Whatmann 1) using 0.9% saline solution as the
mobile phase. Radioactivity was measured with a NaI(Tl)
solid scintillation counter.
pH was adjusted to 7 with NaOH 1.0 N.
Second step: preparation of  188Re-FHMA: 1 mL of 188Re-Sn
colloid and 1.8 mL of ferrous sulfate solution (7.36 mg/
mL) were mixed in a centrifuge tube, 0.7 mL of NaOH 0.1
N and 1.1 mL of saline solution were added. The contents
of the tube were vortexed for 10 seconds. 0.6 mL of Poliv-
inylpirrolidone (PVP) solution (16 mg/mL) were added,
vortexed and centrifuged at 1400 rpm for 4 minutes.
The precipitate particles were separated and the labeled
FHMA were washed as follows.
188Re-FHMA were mixed with 3 mL of a PVP solution (16
mg/mL, pH 8.5), vortexed and centrifuged at 1400 rpm
for 4 minutes. The supernatant and the macroaggregate
were separated and the activity of both was measured in a
dose calibrator.
The  188Re-FHMA was resuspended in 1.5 mL of saline
solution and 1.0 mL of phosphate buffer 0.2 M (pH 7.5).
The percentage of bound activity was determined by
measuring the activity of both precipitate and supernatant
solution in a dose calibrator system. From these data the
percentage of FHMA labeled yield was calculated.
Physical characterization of the radiopharmaceuticals
Non-radioactive forms of the radiopharmaceuticals were
prepared using tracer quantities of potassium perrhenate
in saline solution in volumes and concentrations corre-
sponding to those of generator eluate.
The number, volume and area of the radiopharmaceuti-
cals particles were analyzed with a laser diffraction particle
size analyzer. Particles size were grouped in the following
ranges, <2 µm, 2–10 µm, 10–40 µm and >40 µm.
Stability studies
In vitro and in vivo stability studies were performed for
the 188Re-Sn colloid, 188Re-HA particles (Direct method)
and for the 188Re-Sn-FHMA.
In vitro stability studies
Each radiopharmaceutical was kept at room temperature
or at 37°C for 2 and 24 hr after labeling. Stability of 188Re-
Sn colloid, 188Re-HA particles and 188Re-Sn-FHMA was
assessed in saline solution, ascorbic acid (pH 5)/human
serum and saline solution/human serum, respectively. In
every case the percentage of bound activity was measured.
In vivo stability studies
Urine samples were collected during the first 24 hr post-
radiopharmaceutical administration.
Biodistribution in New Zealand adult male rabbits (4 kg
weight) was performed. The animals were sacrificed with
an overdose of sodium thiopenthal after 48 hr of intraar-
ticular administration of 188Re-Sn colloid, 188Re-HA direct
method and 188Re-Sn-FHMA (1 mCi/mL).
Knee joint, thyroid, heart, urinary bladder, gall bladder,
liver, spleen, lungs, stomach, intestines, kidney, muscle,
bone, blood and urine samples were collected and radio-
activity was measured in a scintillation counter.
Scintigraphic studies
The New Zealand rabbits were anesthetized by intramus-
cular administration of 50 mg/kg of ketamine and 10 mg/
mL of xilazine. Scintigraphic images were acquired with a
Sophy Camera DSX, with medium energy collimator, at 0,
24 and 48 hr after intraarticular administration of each
radiopharmaceutical.
Table 1: Radiopharmaceutical stability during 24 hr after labeling as percentage
188Re-Sn 188Re-Sn-FHMA 188Re-HA
Saline solution 100 90 .....
Ascorbic acid ..... ...... 65
Human serum ..... 86 69BMC Nuclear Medicine 2004, 4 http://www.biomedcentral.com/1471-2385/4/1
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Results
Labeling procedures
188Re-Sn colloid was obtained with a radiochemical purity
over 95% and was stable for 24 hr, as was previously
reported [11].
188Re-HA was labeled according to Chinol M. procedure
[1]. The first step which consisted in 188Re-HEDP prepara-
tion, was successfully achieved (radiochemical purity over
99%). However in the second step the percentage of
bound 188Re-HA was not higher than 5%. In consequence
a second technique called "direct method" was adopted,
similar to that described by Kothari et al [9] with minor
modifications. In this case the percentage of bound activ-
ity was 55% (n = 3).
188Re-Sn-FHMA was first labeled according to the proce-
dure used with 195Dy described by Castro M and Portilla
A [10]. The percentage of bound activity obtained with
this procedure was 1.2%. A technique in two steps intro-
ducing tin as a reducing agent improved the labeling
yields to 91.8% (n = 3).
Physical characterization of the radiopharmaceuticals
There are no significant differences between the radiop-
harmaceuticals formulated taking into account number
and volume of the particles that are in the critical range
(less than 2 micrometers and over 40 micrometers) as can
be seen in Table 2. However differences arise when we
study the surface area of each formulation analyzed.
Stability studies
In vitro stability studies
Stability studies for 188Re-Sn were carried out in saline
solution, showing that the radiopharmaceutical was sta-
ble for 24 hr at room temperature (Table 1).
For  188Re-HA the stability studies were carried out in
human serum and ascorbic acid, showing that the radiop-
harmaceutical was stable for 24 hr at 37°C (Table 1).
Stability studies for 188Re-Sn-FHMA in saline solution and
human serum were performed, showing that the radiop-
harmaceutical was stable for 24 hr at 37°C (Table 1).
In vivo stability studies
Renal elimination of 188Re-Sn colloid and 188Re-Sn-FHMA
was detected by activity measurements in urine samples
during the first 12 hr post-radiopharmaceutical injection.
Activities per gram of selected tissue/organs including the
knee joint after 48 hr of the radiopharmaceutical intraar-
ticular administration to New Zealand rabbits are shown
in Table 3.
The percentage of activity retained in the knee joint for
each radiopharmaceutical at 48 hr post injection was over
90% of residual activity in the whole body (Figure 1).
Nevertheless the percentage of injected activity in the knee
joint after 48 hr for each radiopharmaceutical was signifi-
cantly different. The 188Re-Sn colloid had the highest per-
centage of retention in the knee joint (Figure 2).
Scintigraphic studies
The scintigraphic images of the rabbits, at 0, 24 and 48 hr
post administration, indicate relevant activity only in the
knee, and negligible activity in the rest of the organism for
each formulation (Figure 3).
Discussion
The labeling procedures for 188Re-HA and 188Re-Sn-FHMA
included multiple centrifugation and separation steps. In
both cases modifications from previous techniques had to
be adopted to improve the percentage of bound activity to
the particles. For 188Re-HA a two step procedure (used for
Samarium-153 and Rhenium-186 labeled hydroxyapa-
tite) [1] was discarded and a direct labeling technique was
tried [9], that improved the percentage of bound activity
from less than 5% to over 55%.
For the ferric hydroxide macroaggregates labeling a proce-
dure originally developed for 195Dy was followed. This
method did not succeed for 188Re (less than 2% of bound
activity) because of the differences in reduction potentials
of the two radionuclides. Therefore several reducing
agents were tested and the best results were obtained with
the two step procedure using tin to reduce the 188ReO4
-
prior to the labeling (coating) of the ferric hydroxide mac-
roaggregate (over 90% of bound activity was obtained).
Table 2: Radiopharmaceutical particles distribution according to size, volume and surface
188Re-Sn 188Re-Sn-FHMA 188Re-HA
Particle size Number Volume Surface Number Volume Surface Number Volume Surface
< 2 um 90 8 31 95 2 22 98 7 53
2 to 10 um 9,9 63 61 4 34 42 1,8 10 19
10 to 40 um 0,1 29 8 1 64 36 0,2 83 28
>40 um 0 1 0 0 0 0 0 0 0BMC Nuclear Medicine 2004, 4 http://www.biomedcentral.com/1471-2385/4/1
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Percentage of residual whole body activity in the knee joint at 48 hr post-administration Figure 1
Percentage of residual whole body activity in the knee joint at 48 hr post-administration.
Table 3: Radiopharmaceutical biodistribution at 48 hr after injection
Activity per gram of organ
Organ 188Re-Sn 188Re-Sn-FHMA 188Re-HA
Thyroid 9,58E-04 6,03E-04 3,31E-04
Lungs 9,18E-04 1,55E-03 8,68E-05
Kidneys 4,39E-04 2,64E-02 3,07E-03
Liver 1,62E-03 2,46E-03 1,68E-04
Spleen 1,53E-04 3,43E-03 9,33E-05
Stomach 3,64E-04 1,98E-04 3,52E-05
Muscle 5,64E-05 2,27E-04 1,62E-04
Bone 3,98E-03 2,62E-04 1,15E-04
Intestines 3,20E-03 3,54E-03 5,76E-04
Heart 3,39E-04 3,17E-04 4,83E-05
Blood 2,67E-04 9,75E-04 2,43E-04
Urine 2,34E-03 1,16E-02 6,52E-03
Urinary bladder 2,56E-03 4,66E-04 1,64E-03
Gall bladder 6,25E-03 5,36E-03 2,08E-04
Joint (knee) 1,01E+00 9,99E-01 6,21E-01
All activities were corrected to the sacrifice time
93,6 91,4
95,7
0
20
40
60
80
100
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The labeling procedures for both 188Re-HA and 188Re-Sn-
FHMA was time consuming and difficult to perform in a
nuclear medicine facility in sterile conditions. On the
other hand the 188Re-Sn colloid is easily labeled in sterile
conditions with high radiochemical purity (over 95%)
and was stable for a 48 hr period.
It has been well established in previous works [8] that
radiopharmaceutical particle size must be small enough
to be phagocyted by the superficial cells of the sinovium
(<40 µm) but not so small as to facilitate fast biological
clearance by diffusion from the joint (>2 µm). For each of
the radiopharmaceuticals tested, the activity remaining in
the knee joint at 48 hr represented over 90% of the activity
detected in the whole body, with no significant levels
being detected in other tissues or organs, including liver
and spleen.
Therefore any radiopharmaceutical not remaining in the
knee joint must be rapidly excreted. This was confirmed
by activity renal clearance during the first 12 hr, probably
associated with very small particles, much less than 2 µm.
However the percentage of injected activity in the knee
joint was significantly different for the preparations
tested. The 188Re-Sn colloid had the highest retention
(69.5%) followed by 188Re-Sn-FHMA (55.1%) and finally
188Re-HA particles (33.6%) (Figure 2).
Both 188Re-Sn colloid and 188Re-HA particle results were
in agreement with the distribution percentage according
to the surface area criteria (Table 2). It can be seen for the
tin colloid that the greatest percentage surface area corre-
sponds to the 2 to 10 micrometers range. 188Re-HA had
the biggest loss of the injected activity because 53% of the
Percentage of injected activity in the knee joint at 48 hr post-administration Figure 2
Percentage of injected activity in the knee joint at 48 hr post-administration.
69,5
55,1
33,6
0
10
20
30
40
50
60
70
188Re-Sn 188Re-Sn-FHMA 188Re-HABMC Nuclear Medicine 2004, 4 http://www.biomedcentral.com/1471-2385/4/1
Page 8 of 10
(page number not for citation purposes)
Scintigraphic images at 0, 24 and 48 hr for 188Re-Sn, 188Re-Sn-FHMA and 188Re-HA Figure 3
Scintigraphic images at 0, 24 and 48 hr for 188Re-Sn, 188Re-Sn-FHMA and 188Re-HA.BMC Nuclear Medicine 2004, 4 http://www.biomedcentral.com/1471-2385/4/1
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surface area corresponds to particles of less than 2 µm
which could leak from the joint.
Nevertheless apparently anomalous values were obtained
for  188Re-Sn-FHMA distribution (surface area criteria,
Table 2) where only 22% of the particle surface corre-
sponds to the range lower than 2 µm and the residual
activity in the knee was 55% instead of 80%. The ferric
hydroxide radiopharmaceutical is actually a macroaggre-
gate coated by a tin colloid as it was observed by electronic
microscopy of HSA microspheres labeled with 188Re [12].
The macroaggregate labeling (coating) may be achieved
by a combination of the reduction of 188ReO4
- by tin and
a particle surface related co precipitation effect of a ferric
hydroxide macroaggregate with a tin colloid. The dissoci-
ation of 188Re-Sn from the ferric hydroxide macroaggre-
gate could happen in a certain range, and as a
consequence we postulated that the fraction smaller than
2 µm could leak from the joint. So actually the leakage of
188Re-Sn-FHMA would be by ferric hydroxide macroaggre-
gates smaller than 2 micrometers and the 188Re-Sn colloid
dissociated with a size of less than 2 µm.
We found that the range from 2 to 10 micrometers was the
optimum because the particles were phagocyted and
remained in the target area for at least 48 hr.
From the point of view of the radiological security of the
patient, the best radiopharmaceutical is that one with a
greater percentage of the injected dose retained in the
joint because a smaller activity amount had to be injected
to obtain the desired radiation dose. This fact takes into
account radioprotection principles for the patient in order
to minimize absorbed dose. The three formulations tested
had rapid renal clearance and showed negligible retention
in other tissues or organs other than the knee. Therefore
188Re-Sn which had the greatest retention in the knee
(69.1%) was the radiopharmaceutical that could give the
desired effect with the lowest absorbed dose in the
patient's whole body.
Conclusions
188Re-Sn could be selected as the best formulation for syn-
ovectomy therapy taking into account ease of labeling
procedure, kit formulation, minimum facilities required,
suitable physical and biological characteristics and the
lowest absorbed dose for the patient. Because of this the
highest benefit/risk relation was found for 188Re-Sn in
comparison with 188Re-Sn-FHMA and 188Re-HA.
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